Helios Launches with Blood Test Claiming to Predict Health Risks, Drawing Comparisons to Theranos

Deep News18:20

A startup called Helios has emerged from stealth mode, claiming it can deliver health assessments and disease risk predictions from a single drop of blood.

As public fascination with the Theranos saga resurfaces, the two founders, Omar Abudayyeh and Jonathan Gootenberg, made a joke by spending roughly $12 to buy the domain theranosbutworks.com.

That domain redirects to the website of Helios, their 16-month-old blood health testing company, which officially launched on Wednesday.

Abudayyeh, 36, and Gootenberg, 35, say that using a non-invasive blood collection device to gather a single drop of blood, the company can test for more than 1,000 proteins in the human body to assess current health status and predict the risk of developing conditions such as heart failure, blood cancers, and Alzheimer's disease over the next decade.

Earlier this year, Abudayyeh, Gootenberg, and a third co-founder, Youssof Badran, a scientist and physician at Massachusetts General Hospital, advanced Helios through the Y Combinator incubator program.

Abudayyeh recalled that during fundraising, many potential investors gave similar feedback: "It sounds like Theranos, but this time it's real. We'd love to talk."

Ultimately, the company raised $2.3 million in seed funding from Y Combinator, venture firm Formation, and angel investors.

Helios is one of many companies pursuing proteomics testing, which examines the various proteins that cells, tissues, and organs continuously produce. Earlier this year, Illumina acquired proteomics company SomaLogic, while Thermo Fisher acquired Olink in 2024. Vero Bioscience, a spinout from Stanford scientist Tony Wyss-Coray's lab, is also developing a blood test that uses protein markers to measure the biological age of different organs.

Pharmaceutical companies use proteomics for new drug development, while universities and medical institutions use it for disease research and diagnosis. Recently, how to get ordinary consumers to routinely use this kind of testing data has drawn significant attention, partly due to the rising popularity of the longevity science sector. Protein markers can provide a real-time snapshot of health and can be used to track whether lifestyle changes and interventions are working.

Proteomics can uncover heart or other health risks that standard blood tests cannot detect, creating opportunities for early intervention. A presentation by Novo Nordisk at an aging research and drug development conference in October further fueled industry enthusiasm for proteomics. The company collected blood samples from participants at enrollment in clinical trials for its weight-loss drugs Ozempic and Wegovy and re-tested them months later; proteomic analysis revealed that participants taking the medication showed slower organ aging compared to the placebo group.

The technology used in proteomics is completely different from that of Theranos. Theranos claimed its device could perform hundreds of routine tests from just a small amount of blood. In Nathan Fielder's film about the Theranos scandal, "The Inventor," Elizabeth Holmes and her partner Billy Evans are depicted as pitching a "Theranos 2.0" plan to investors.

Evans is the founder of Haemanthus, an Austin, Texas-based diagnostics startup that, according to a 2025 New York Times report, developed a device capable of testing blood, urine, and saliva.

Helios's device is attached to the upper arm with tape; pressing a button lightly pricks the arm to collect a drop of blood, which is stored in a test cartridge. The device is then removed, sealed in a bag, and mailed to Helios's lab in Boston.

After protein testing is completed at the lab, Helios's AI model evaluates the function of organs including the heart, liver, brain, and kidneys, and calculates the risk of developing major diseases in the future. An AI assistant also provides recommendations on diet, lifestyle adjustments, dietary supplements, or medications.

The algorithm's predictions and recommendations are trained on more than 80,000 scientific papers, genetic studies, and clinical trial results.

The test is set to launch in early 2027, initially available only through longevity clinics and concierge doctor channels. Helios's pricing ranges from $250 to $600 per test, depending on clinic purchase volumes. Abudayyeh and Gootenberg said they plan to launch direct-to-consumer sales on their website by the end of 2027, with consumer pricing yet to be determined.

The two founders were undergraduate classmates at MIT and later pursued their doctorates together in the lab of CRISPR gene-editing pioneer Feng Zhang. They co-authored multiple top-journal papers in the CRISPR and gene-editing fields; before founding Helios, they had already started five companies together, including Sherlock Biosciences, a CRISPR diagnostics company acquired by OraSure in 2024, and Tome Biosciences, a gene-editing startup that raised over $200 million before running out of funds and shutting down in 2024.

Gootenberg and Abudayyeh watched "The Inventor" together, and one scene left a deep impression on Gootenberg: Holmes was about to report to prison, yet Evans was still enthusiastically outlining a "Theranos 2.0" vision to investors alongside her. "Even after a scandal like that, people were still willing to listen. That says a lot about the real demand from the technology, society, and investors. It was very striking," Gootenberg said. "The vision Theranos promised back then is still very compelling and resonates today," Abudayyeh said.

In a video on Helios's website, Abudayyeh acknowledged: "Yes, we know, technology has promised before that a single drop of blood could diagnose you." The video simultaneously displays their academic credentials, signaling that they are different from Theranos. The video also explains that proteomics technology has already been validated in laboratories and companies around the world.

Despite the growing enthusiasm for proteomics testing, Vero's Wyss-Coray said he still has to deal with the inevitable comparison: "When I give talks, I start by saying, 'This is not Theranos,' which usually gets a laugh."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment